Amgen Reports 24% EPS Growth, Revenue Surges 9% in Q1 2025

Amgen reported a strong first quarter, with non-GAAP earnings per share rising 24% to $4.90 and revenues growing between 8.7% and 11% year-over-year, surpassing analyst expectations. Product sales increased 11%, with 14 drugs, including Repatha and Tezspire, showing double-digit growth, and notable progress in new drug development such as FDA approval for UPLIZNA and early-stage trials for weight-loss candidates. Analysts remain bullish, projecting a potential 12.5% to 22.36% upside in the stock price and assigning Amgen an 'Outperform' rating. The company has consistently beaten earnings estimates for the last four quarters and maintains robust financial health, supported by increased R&D investment and a raised dividend. Despite a slight deceleration in growth and anticipated biosimilar competition for key drugs like Prolia, Amgen's diversified portfolio and focus on innovation bolster investor confidence. Regulatory challenges and market unpredictability remain, but Amgen's strategic initiatives position it well for continued resilience in the biopharmaceutical sector.